Global Ophthalmic Drugs Market 2018-2023: Analysis by Drugs and Geography - ResearchAndMarkets.com

August 27, 2018

DUBLIN--(BUSINESS WIRE)--Aug 27, 2018--The “Global Ophthalmic Drugs Market - Segmented by Drugs and Geography - Growth, Trends, and Forecast (2018 - 2023)” report has been added to ResearchAndMarkets.com’s offering.

The global ophthalmic drugs market is expected to register a CAGR of 4.15% during the forecast period of 2018-2023.

Rise in Cataract Volume: Cataract volume has seen a rapid increase in recent years. While the aging population is expected to burden all areas of healthcare, ophthalmologists provide approximately 90% of their procedure-based services to seniors. Cataract surgery is the most frequent surgical procedure performed in many countries, providing significant improvements in the quality of life to the elderly population at a low cost. Other factors, such as availability of new drugs and the prevalence of eye diseases are going to drive the market.

Other Key Dynamics

Strict FDA Guidelines for Drug Approval North America to Dominate the Market

Notable Developments

Bausch & Lomb got Vyzulta approved for reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Spark Therapeutics developed Luxturna, which is specifically indicated for vision loss, got FDA approval.

Key Topics Covered

1. Introduction

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview

6. Drivers, Restraints, Opportunities, and Challenges (DROC) Analysis

7. Market Segmentation

8. Competitive Landscape

9. Key Players

Alcon Allergan Bausch & Lomb Incorporated Bayer AG Hoya Corporation Johnson & Johnson Vision Care Inc. Novartis AG Pfizer Inc. Santen Pharmaceuticals Co. Ltd. Valeant

10. Future of the Market

For more information about this report visit https://www.researchandmarkets.com/research/mpbgt6/global_ophthalmic?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180827005363/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Optical Disorders Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 08/27/2018 10:20 AM/DISC: 08/27/2018 10:21 AM


Update hourly